Bellerophon Therapeutics (NASDAQ:BLPH) Now Covered by StockNews.com

StockNews.com began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research note issued to investors on Sunday. The firm issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

BLPH opened at $0.06 on Friday. Bellerophon Therapeutics has a twelve month low of $0.03 and a twelve month high of $0.10. The company has a fifty day moving average of $0.04 and a 200-day moving average of $0.05. The stock has a market cap of $672,815.00, a PE ratio of -0.07 and a beta of 0.71.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.